Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market
Biogen's drug is poised to become top dog among many oral MS drugs, including Novartis' approved Gilenya, analysts say.
Biogen's drug is poised to become top dog among many oral MS drugs, including Novartis' approved Gilenya, analysts say.